Pacira | PCRX - Cash And Equivalent


Pacira reported $205.88M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Astellas Pharma JPY 281.6B 93.23B Mar/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Cara Therapeutics USD 19.85M 883K Mar/2026
Coherus Biosciences USD 82.92M 32.32M Jun/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
J&J USD 20.42B 1.27B Jun/2026
Ligand Pharmaceuticals USD 1.01B 891.62M Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 205.88M 61.57M Jun/2026
Perrigo USD 357.2M 174.4M Mar/2026
Pfizer USD 976M 727M Jun/2026
Supernus Pharmaceuticals USD 179.95M 4.92M Jun/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
Xeris Pharmaceuticals USD 121.75M 10M Jun/2026
Zoetis USD 1.48B 465M Jun/2026